Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Stock Price Down 2.8% – Time to Sell?
by Doug Wharley · The Cerbat GemArmata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP – Get Free Report)’s share price dropped 2.8% on Wednesday . The stock traded as low as $7.37 and last traded at $7.56. Approximately 29,568 shares changed hands during trading, a decline of 55% from the average daily volume of 65,741 shares. The stock had previously closed at $7.78.
Analyst Upgrades and Downgrades
ARMP has been the topic of several research reports. HC Wainwright raised their price objective on shares of Armata Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. Zacks Research upgraded shares of Armata Pharmaceuticals to a “hold” rating in a research report on Monday, May 18th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $15.00.
Check Out Our Latest Analysis on Armata Pharmaceuticals
Armata Pharmaceuticals Stock Performance
The company has a market cap of $278.26 million, a PE ratio of -0.97 and a beta of 1.21. The business’s 50-day moving average is $9.70 and its 200 day moving average is $8.40.
Armata Pharmaceuticals (NYSEAMERICAN:ARMP – Get Free Report) last issued its earnings results on Wednesday, May 13th. The company reported ($3.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($2.78). The company had revenue of $0.79 million for the quarter, compared to the consensus estimate of $0.74 million. Equities research analysts anticipate that Armata Pharmaceuticals, Inc. will post -1.88 EPS for the current fiscal year.
Hedge Funds Weigh In On Armata Pharmaceuticals
Large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE raised its position in Armata Pharmaceuticals by 233.2% in the 1st quarter. Bank of America Corp DE now owns 11,714 shares of the company’s stock worth $120,000 after purchasing an additional 8,198 shares during the period. Jane Street Group LLC purchased a new position in Armata Pharmaceuticals in the 4th quarter worth $108,000. Millennium Management LLC purchased a new position in Armata Pharmaceuticals in the 4th quarter worth $164,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Armata Pharmaceuticals in the fourth quarter valued at about $177,000. Finally, SeaCrest Wealth Management LLC increased its position in shares of Armata Pharmaceuticals by 17.3% in the fourth quarter. SeaCrest Wealth Management LLC now owns 40,988 shares of the company’s stock valued at $274,000 after acquiring an additional 6,034 shares during the period. Hedge funds and other institutional investors own 3.57% of the company’s stock.
Armata Pharmaceuticals Company Profile
Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.
Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.